Relmada Therapeutics doses first patient in Relight Phase 3 trial

Relmada Therapeutics announced the dosing of the first patient in the Relight Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of Major Depressive Disorder, or MDD. The Relight Phase 3 trial has a planned enrollment of approximately 300 patients. Relight is a randomized, double-blind, placebo-controlled, four-week trial, evaluating the efficacy and safety of REL-1017 as an adjunctive treatment of MDD in patients experiencing inadequate response to an ongoing background antidepressant treatment. The primary endpoint is the change in the MADRS total score from baseline to Day 28 for REL-1017 compared to placebo.